Clinical trials for Lymphoma
104 currently recruiting clinical trials
Looking for clinical trials?
Clinical trial search is a complex process, with countless criteria to consider. Our AI assistant navigates this complexity with precise, expert-level analysis of the most relevant trials based on your medical profile. Our database is fully up to date, so you see only actively recruiting sites. It's fast and easy:
- Create your account
- Copy-paste your latest medical report
- Our AI-based assistant does the rest for you
Whether you are a patient or a doctor, create an account to find and apply for the most relevant clinical trials:
Phase 1 / Phase 2
Lymphoma
#NCT07519772
#2025-523005-15-00
Lymphome folliculaire
Required histologic types
B cell lymphoma
Required histologic sub types
Follicular lymphoma
Required central nervous system lesions
None
Required immunophenotypic profiles
CD19
Required number of previous lines of therapy
2
3 or more
Excluded previous treatments
Systemic Treatment-Naive
1 recruiting site
Merck Sharp & Dohme LLC
Phase 1 / Phase 2
Lymphoma
#NCT07519772
#2025-523005-15-00
Lymphome diffus à grandes cellules B
Required histologic types
B cell lymphoma
Required histologic sub types
Large B cell lymphoma
Required central nervous system lesions
None
Required immunophenotypic profiles
CD19
Required number of previous lines of therapy
2
3 or more
Required previous treatments
Car-T
Autologous stem cell transplant
Allogeneic stem cell transplant
Excluded previous treatments
Systemic Treatment-Naive
1 recruiting site
Merck Sharp & Dohme LLC
Phase 1 / Phase 2
Lymphoma
CLL & Richter's syndrome
#NCT05006716
Required histologic types
B cell lymphoma
CLL (Chronic Lymphocytic Leukemia)
Richter's syndrome
Required histologic sub types
Large B cell lymphoma
Mantel cell lymphoma
Follicular lymphoma
Marginal zone lymphoma
Waldenström lymphoma
Lymphocytic lymphoma
Required central nervous system lesions
None
Required number of previous lines of therapy
1
2
3 or more
Excluded previous treatments
Systemic Treatment-Naive
9 recruiting sites
BeOne Medecines
Phase 1 / Phase 2
Lymphoma
#NCT06137144
Module 2 Cohorte 1
Required histologic types
Hodgkin lymphoma
Required number of previous lines of therapy
1
2
3 or more
Excluded previous treatments
Systemic Treatment-Naive
4 recruiting sites
AstraZeneca
Phase 1 / Phase 2
Lymphoma
#NCT06137144
Module 1 Cohorte 2
Required histologic types
Hodgkin lymphoma
Required disease stage
Disseminated (stage III and IV)
Required number of previous lines of therapy
None
Required previous treatments
Chemotherapy
Excluded previous treatments
Systemic Treatment-Naive
4 recruiting sites
AstraZeneca
Phase 1 / Phase 2
Lymphoma
#NCT06137144
Module 1 Cohorte 1
Required histologic types
Hodgkin lymphoma
Required number of previous lines of therapy
2
3 or more
Required previous treatments
Immunotherapy
Chemotherapy
Excluded previous treatments
Systemic Treatment-Naive
4 recruiting sites
AstraZeneca
Phase 1 / Phase 2
Lymphoma
#NCT06137144
Module 1 Cohorte 3
Required histologic types
T cell lymphoma
Required histologic sub types
Peripheral T cell lymphoma
Required disease stage
Disseminated (stage III and IV)
Required number of previous lines of therapy
1
2
3 or more
Excluded previous treatments
Systemic Treatment-Naive
4 recruiting sites
AstraZeneca
Phase 1 / Phase 2
Lymphoma
#NCT04502394
Cohorte 1 (TP53wt R/R DLBCL)
Required histologic types
B cell lymphoma
Required histologic sub types
Large B cell lymphoma
Required number of previous lines of therapy
1
2
3 or more
Excluded genetic anomalies
TP53
Excluded previous treatments
Systemic Treatment-Naive
3 recruiting sites
Kartos Therapeutics
Phase 1 / Phase 2
Lymphoma
#NCT06697184
#2024-518829-15-00
Bras Lymphome du manteau R/R (Bras 1C et 2B)
Required histologic types
B cell lymphoma
Required histologic sub types
Mantel cell lymphoma
Required number of previous lines of therapy
1
2
3 or more
Excluded previous treatments
Systemic Treatment-Naive
3 recruiting sites
BeOne Medecines
Phase 1 / Phase 2
Lymphoma
CLL & Richter's syndrome
Acute leukemia
Myelodysplastic Syndromes (MDS) and Myeloproliferative Neoplasms (MPN)
#NCT07220616
#2025-522595-87-00
Required central nervous system lesions
None
Treated / Controled
Required number of previous lines of therapy
1
2
3 or more
Excluded previous treatments
Systemic Treatment-Naive
Allogeneic stem cell transplant
3 recruiting sites
Daiichi Sankyo